Skip to main content
News & Events
Podcasts & Webinars
You are here
Novosanis launches volume variants of Colli-Pee® offering new applications in urine testing
We are excited to announce the launch of volume variants of Colli-Pee ® , our innovative urine-capturing device...
Novosanis enters into distribution deal with Fujirebio
Novosanis announces deal with Fujirebio, a global leader in the field of in vitro diagnostics (IVD). Using our Colli-...
Novosanis acquired by OraSure Technologies Inc
Wijnegem, Belgium, January 8, 2019: Novosanis, a privately-held, Belgian company founded as a spinoff company from the...
European Patent granted for Colli-Pee
Novosanis announced today that the European Patent Office (EPO) has granted the company's patent application in Europe...
Colli-Pee approved by Mexican Health Authority
Wijnegem, Belgium, November 8, 2018: Novosanis, an innovative developer and producer of medical devices, announced...
Novosanis obtains regulatory approval for Colli-Pee in Brazil
Wijnegem, Belgium, July 26 2018: Novosanis announced today that Colli-Pee a non-invasive self-sampling device suited...
Colli-Pee with UCM preservative CE certified
Novosanis, an innovative developer and producer of medical devices, announced today that Colli-Pee, a self-sampling...
Colli-Pee recognized at the prestigious Henry Van de Velde Awards
Novosanis and Voxdale have been awarded the prestigious Henry Van de Velde Award in Design for Healthcare.
Novosanis receives Interreg CrossCare grant for its Colli-Pee™ device
Interreg CrossCare grant allows Novosanis to build a next-generation Colli-Pee™ device
Novosanis signs agreement with MDxHealth
Novosanis develops UrNCollect TM for SelectMDx for Prostate Cancer IVD kit of MDxHealth
First CE marked HPV test offering possibility to use first-void urine
Novosanis, a medical device company based in Wijnegem Belgium, together with GeneFirst, a molecular diagnostic company...
Novosanis participates in Belgian Royal Mission to Japan
Novosanis considers Japan as an important market due to its innovative vision towards healthcare and diagnostics.